Mouse anti-Human IGFBP-3 Monoclonal Antibody | anti-IGFBP-3 antibody

Monoclonal Mouse anti Human IGFBP-3

Cat. Num. AAA550042

• Reactivity: Human
• Purity: The IgG fraction of the tissue culture supernatant was purified by Protein A affinity chromatography.
• Synonyms: IGFBP-3; Monoclonal Antibody; Monoclonal Mouse anti Human IGFBP-3; igfbp3; igfbp-3; monoclonal; mab; anti-IGFBP-3 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2a
• Clone Number: SBH10
• Purity/Purification: The IgG fraction of the tissue culture supernatant was purified by Protein A affinity chromatography.
• Form/Format: lyophilized from sterile filtered solution at a concentration of 1mg/ml in PBS with 5% trehalose.
• Sequence Length: 291

• Application Notes: ELISA: This antibody can be used at 0.5-1ug/mLwith the appropriate secondary reagents to detect human IGFBP-3. The detection limit for Human IGFBP3 is approximately 0.1ng/well.; Western blot:This monoclonal antibody has been tested in WB analysis of human IGFBP-3. A suitable range of concentrations of this antibody for WB detection is 0.5-2 ug/ml.The detection limit for IGFBP3 is approximately 4ng/lane under non-reducing conditions and 2ng/lane under reducing conditions.
• Host Note: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with recombinant E. coli-derived Human IGFBP-3.
• Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
• Preparation and Storage: The lyophilized antibody is stable for at least 1 year from date of receipt at -20 degree C.; Upon reconstitution, this antibody can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months without detectable loss of activity. ; ; Avoid repeated freeze/thaw cycles.

Related Product Information for anti-IGFBP-3 antibody

IGFBPs are synthesized in the liver and are produced also by various tumor cell lines and cell types. IGFBPs are high affinity binding proteins for IGF. The major fraction of both types of IGF circulating in the blood are bound non- covalently to these carrier proteins. IGF binding proteins modulate IGF activities by increasing their plasma half lives and by inhibiting or promoting the interactions of IGF with receptors on certain target cells. In addition these binding proteins provide a reservoir for IGF in pericellular spaces. Some IGFBPs also have stimulating effects in vitro and some may inhibit the growth of cells. IGFBP1 is found predominantly in the placenta and the amniotic fluid. The predominant sites of IGFBP1 transcription in the human fetal kidney are those with most active differentiation. Elevated serum levels have been observed in patients with Laron-type dwarfism and Growth hormone deficiency. High serum levels of IGFBP1 are found in newborns and it has been suggested that this could be important in protecting them from hypoglycemia.

Product Categories/Family for anti-IGFBP-3 antibody

Monoclonal

References

• randomized gh trial with two different dosages in combination with a gnrh analogue in short sga children: effects on metabolic profile, serum growth hormone, igf-i and IGFBP-3 levels .Eur. J. Endocrinol., Feb 2010; 10.1530/EJE-09-1113.
• nuclear export and mitochondrial and er localization of IGFBP-3 regulates its apoptotic properties .Endocr. Relat. Cancer, Jan 2010; 10.1677/ERC-09-0106.
• association between hepatic steatosis and serum igf1 and IGFBP-3 levels in a population-based sample .Eur. J. Endocrinol., Nov 2009; 161: 705 - 713.
• the expression and function of IGFBP-3 in normal and malignant breast tissue .Anticancer Res, Oct 2009; 29: 3785 - 3790.
• prognostic role of insulin-like growth factor receptor-1 (igfr-1) and insulin-like growth factor binding protein-3 (IGFBP-3) expression in small cell lung cancer .ASCO Meeting Abstracts, May 2009; 27: e22155.